SUICIDAL DEPRESSED PATIENTS RESPOND LESS WELL TO ANTIDEPRESSANTS IN THE SHORT TERM

Depression and Anxiety

Volumn 33, Issue 6, 2016, Pages 483-494

  Lopez Castroman, Jorge ^a,b,c   Jaussent, Isabelle ^b   Gorwood, Philip ^d,e,f   Courtet, Philippe ^b,c,g  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSERM U1061   (France)

^c FONDATION FONDAMENTAL   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

assessment; depression severity; pharmacological therapy; suicidal ideation; suicide attempt; treatment

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRANCE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PROSPECTIVE STUDY; QUANTITATIVE STUDY; QUESTIONNAIRE; REMISSION; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESPONSE; DEPRESSION; OUTCOME ASSESSMENT;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84959147322     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22473     Document Type: Article

References (68)

1. Gusmão R, Quintão S, McDaid D, et al. Antidepressant utilization and suicide in Europe: an Ecological Multi-National Study. PLoS One 2013;8:e66455.
2. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844–850.
3. Holma KM, Melartin TK, Haukka J, et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry 2010;167:801–808.
4. Courtet P, Jaussent I, López-Castromán J, Gorwood P. Poor response to antidepressants predicts new suicidal ideas and behavior in depressed outpatients. Eur Neuropsychopharmacol 2014;24:1650–1658.
5. Cougnard A, Verdoux H, Grolleau A, et al. Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model. Psychol Med 2009;39:1307–1315.
6. Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580–587.
7. Rutz W, Knorring von L, Wålinder J. Long-term effects of an educational program for general practitioners given by the Swedish Committee for the Prevention and Treatment of Depression. Acta Psychiatr Scand 1992;85:83–88.
8. Rihmer Z, Gonda X, Faludi G, Fountoulakis KN. Positive antidepressant pharmacotherapy in reducing suicide morbidity and mortality in unipolar depression. Eur Psychiat Rev 2008;2:59–62.
9. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002;68:167–181.
10. Isacsson G, Holmgren A, Ösby U, Ahlner J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995–2005. Acta Psychiatr Scand 2009;120:37–44.
11. Ludwig J, Marcotte DE, Norberg K. Anti-depressants and suicide. J Health Econ 2009;28:659–676.
12. Isacsson G, Rich C. Antidepressant medication prevents suicide: a review of ecological studies. Eur Psychiatr Rev 2008;1:24–26.
13. Isacsson G, Ahlner J. Antidepressants and the risk of suicide in young persons—prescription trends and toxicological analyses. Acta Psychiatr Scand 2014;129:296–302.
14. Barber C, Azrael D, Miller M. Study findings on FDA antidepressant warnings and suicide attempts in young people: a false alarm? BMJ 2014;349:g5645.
15. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 2006;94:3–13.
16. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STARD study. J Affect Disord 2009;117:63–73.
17. Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009;7:1–14.
18. Perlis RH, Beasley CM, Wines JD, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007;76:40–46.
19. Seemüller F, Riedel M, Obermeier M, et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharm 2009;12:181–189.
20. Courtet P, Gottesman II, Jollant F, Gould TD. The neuroscience of suicidal behaviors: what can we expect from endophenotype strategies? Transl Psychiatry 2011;1:1–7.
21. Michel K. Suicide risk factors: a comparison of suicide attempters with suicide completers. Br J Psychiatry 1987;150:78–82.
22. Malhotra K, Schwartz T, Hameed U. Presence of suicidality as a prognostic indicator. J Postgrad Med 2004;50:185–187;discussion 187–188.
23. Perroud N, Uher R, Hauser J, et al. History of suicide attempts among patients with depression in the GENDEP project. J Affect Disord 2010;123:131–137.
24. Pompili M, Baldessarini RJ, Tondo L, et al. Response to intravenous antidepressant treatment by suicidal vs. nonsuicidal depressed patients. J Affect Disord 2010;122:154–158.
25. Valuck RJ, Libby AM, Anderson HD, et al. Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study. Br J Psychiatry 2015. [Epub head of print]
26. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010;15:237–249.
27. Rambelomanana S, Depont F, Forest K, et al. Antidepressants: general practitioners' opinions and clinical practice. Acta Psychiatr Scand 2006;113:460–467.
28. Svanborg P, Åsberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 1994;89:21–28.
29. Seemüller F, Schennach-Wolff R, Obermeier M, et al. Does early improvement in major depression protect against treatment emergent suicidal ideation? J Affect Disord 2010;124:183–186.
30. Friedman S, Samuelian J-C, Lancrenon S, et al. Three-dimensional structure of the Hospital Anxiety and Depression Scale in a large French primary care population suffering from major depression. Psychiatry Res 2001;104:247–257.
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
32. McDowell I. Measuring Health: A Guide to Rating Scales and Questionnaires. 3rd ed. New York: Oxford University Press; 2006.
33. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
34. Bouvard M, Charles S, Guérin J, et al. Study of Beck's hopelessness scale. Validation and factor analysis. Encephale 1992;18:237–240.
35. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol 1974;42:861–865.
36. Silverman MM, Berman AL, Sanddal ND, et al. Rebuilding the tower of Babel: a revised nomenclature for the study of suicide and suicidal behaviors. Part 1: background, rationale, and methodology. Suicide Life Threat Behav 2007;37:248–263.
37. Friedman ES, Davis LL, Zisook S, et al. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol 2012;22:183–199.
38. Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1983–1989.
39. McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry 2010;71(Suppl 1):16–20.
40. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2015.
41. FDA. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). 2006:1–140.
42. Lenox-Smith A, Martinez JM, Perahia D, et al. Treatment and outcomes for patients with depression who are partial responders to SSRI treatment_ Post-hoc analysis findings from the FINDER European observational study. J Affect Disord 2014;169:149–156.
43. Davidson J, Allgulander C, Pollack MH, et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol Clin Exp 2008;23:519–526.
44. Davidson JRT, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53:188–191.
45. Hung C-I, Wang S-J, Liu C-Y. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder. Depress Anxiety 2009;26:583–591.
46. Gérard A, Liard F, Crochard A, et al. Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment. Neuropsychiatr Dis Treat 2012;8:605–614.
47. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009;42:57–90.
48. Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838–921.
49. Kim S-W, Stewart R, Kim J-M, et al. Relationship between a history of a suicide attempt and treatment outcomes in patients with depression. J Clin Psychopharmacol 2011;31:449–456.
50. Grunebaum MF, Ellis SP, Duan N, et al. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology 2012;37:697–706.
51. Miller M, Swanson SA, Azrael D, et al. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 2014;174:899–909.
52. Courtet P, Lopez-Castroman J, Jaussent I, Gorwood PAPM. Antidepressant dosage and suicidal ideation. JAMA Intern Med 2014;174:1863–1865.
53. Griffiths JJ, Zarate CA, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med 2014;47:S195–S203.
54. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
55. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide—definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010;71:e1–e21.
56. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999;56:617–626.
57. Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry 2004;161:1433–1441.
58. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189–1194.
59. Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition: systematic review and meta-analysis. PLoS One 2014;9:e89944.
60. Christiansen E, Frank Jensen B. Risk of repetition of suicide attempt, suicide or all deaths after an episode of attempted suicide: a register-based survival analysis. Aust NZ J Psychiatry 2007;41:257–265.
61. Haukka J, Suominen K, Partonen T, Lönnqvist J. Determinants and outcomes of serious attempted suicide: a nationwide study in Finland, 1996–2003. Am J Epidemiol 2008;167:1155–1163.
62. Sokero TP, Melartin TK, Rytsälä HJ, et al. Suicidal ideation and attempts among psychiatric patients with major depressive disorder. J Clin Psychiatry 2003;64:1094–1100.
63. Oquendo MA, Malone KM, Mann JJ. Suicide: risk factors and prevention in refractory major depression. Depress Anxiety 1997;5:202–211.
64. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999;156:181–189.
65. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
66. Desseilles M, Perroud N, Guillaume S, et al. Is it valid to measure suicidal ideation by depression rating scales? J Affect Disord 2011;136:398–404.
67. Angst J, Azorin J-M, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68:791–798.
68. Lopez-Castroman J, Courtet P, Baca-García E, Oquendo MA. Identification of suicide risk in bipolar disorder. Bipolar Disord 2015;17:22–23.